From the Editor ’s desk…

Around half of patients with hepatocellular carcinoma (HCC) will receive systemic therapies during their life span. A decade of negative drug trials in HCC followed the approval of sorafenib in 2007. However, in the last 2  years several first- and second-line compounds have shown clinical benefit. Thus, there is now a clear need to define surrogate endpoints that both reliably recapitulate survival benefits and can be assessed before additional efficacious drugs are administered. In this issue, Llovet et al.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Editorial Desk Source Type: research